Health Condition 1: J95- Intraoperative and postproceduralcomplications and disorders of respiratory system, not elsewhere classified Health Condition 2: Y95- Nosocomial condition Health Condition 3: A419- Sepsis, unspecified organism
Conditions
Interventions
Sponsors
The George Institute for Global Health
National University of Singapore
Eligibility
Inclusion criteria
Inclusion criteria: Healthcare-associated bloodstream infection 1) Prescription/commencement of an intravenous antibiotic AND 2) Positive growth of bacterial or Candida spp pathogen(s) identified from blood specimen(s) taken on or after day 3 of admission (Day 1 refers to the day of admission), or within 3 months of significant healthcare exposure; AND 3) Bacterial pathogen(s) in the blood specimen(s) satisfies either of the following: i) one or more non-common commensal bacterial pathogen(s) identified from one or more blood specimens obtained by a culture; OR ii) the same common commensal bacterial pathogen identified from two or more blood specimens collected on separate occasions Ventilator-associated pneumonia 1) Clinical suspicion of VAP; AND 2) Prescription/commencement of an intravenous antibiotic; AND 3) Positive growth of bacterial pathogen(s) identified from respiratory specimen(s) taken on or after day 3 of ventilation.
Exclusion criteria
Exclusion criteria: Healthcare-associated bloodstream infection Patient who has positive growth of organisms belonging to the following genera which are typically causes of community-associated infections and are rarely or are not known to be causes of healthcare-associated infections, or associated with severe immune suppression: a) Burkholderia pseudomallei, b) Brucella spp, including but not limited to, B. melitensis, B. abortus, B. suis, B. canis, c) Campylobacter, Salmonella, Shigella, Listeria, Vibrio and Yersinia. Ventilator-associated pneumonia Patient who has positive growth of organisms belonging to the following genera which are typically causes of community-associated infections and/or are rarely or are not known to be causes of healthcare-associated infections: a) Streptococcus pneumoniae, Streptococcus suis, Haemophilus influenzae, b) Burkholderia pseudomallei, c) Coagulase-negative staphylococci, d) Talaromyces marneffei, e) Mycobacterium Tuberculosis, f) Rapidly growing Mycobacteria, including but not limited to, M. mucogenicum, M. fortuitum, M. abscessus, M. chelonae, M. neoaurum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence & prevalence of multidrug resistant organisms (MDRO) in HA-BSI or VAP quantified in terms of i) hospitalisation, ii) patient bed-days & iii) microbiology culturesTimepoint: Onset of clinical syndrome is on or after day 3 of hospital admission, or within 3 months of significant healthcare exposure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of disease (requirement for intensive care, duration of hospitalisation, functional status at discharge, mortality), types of antibiotic treatmentTimepoint: 28 days from onset of the last infection episode;Attributable mortality of HA-BSI or VAP caused by MDROs versus susceptible organisms or MDROs of different resistance patterns All-cause mortality of HA-BSI or VAP Timepoint: 28 days from onset of the last infection episode;Bacterial species & phenotypic resistance patterns across the study sites from various geographical regions over the study period.Timepoint: Over the study period;Genomic characteristics in terms of bacterial strains/clones, resistance genes across the study sites from various geographical regionsTimepoint: Over the study period | — |
Countries
Bangladesh, Cambodia, India, Indonesia, Malaysia, Mongolia, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, Thailand, Viet Nam
Contacts
Public ContactNikita Bathla
George Institute for Global Health
Outcome results
None listed